EUSOBI 2015: Breast Screening in Brazil
What are the particular challenges for implementing breast screening in Brazil?
The constraints are numerous, from difficulties obtaining information about population demographics to financial resources for implementation of screening and subsequent treatment of patients with cancer. Even in the programmes that do exist there is no active search for women nor control and data management, which characterise organised screening. The lack of demographic data impacts the search for woman who should be screened, and limits the ability to identify and locate patients diagnosed with mammographic abnormalities in need of other intervention, including cancer treatment. Regarding financial resources, there is a significant deficit of radiotherapy and chemotherapy in the country, not only in the poorest states, but also in large, wealthier cities. The delay in treatment limits the benefits of mammographic screening.
What screening technology is available in Brazil?
In Brazil there are two types of healthcare financing: one provided by the government serves 80% of the population. Private health insurance companies cover the remaining 20%. Conditions in these two systems are vastly different. In private services the patients have access to almost all modern technologies such as digital mammography (CR in many cases), ultrasound and MRI. Tomosynthesis is offered to a small group of the population and is not covered by health insurance companies. In the public health system conventional mammography is still quite common. These patients have access to ultrasound, but MRI and tomosynthesis are not widely implemented.
Women with dense breasts are not subject to a different screening programme. Because ultrasonography is an operator-dependent examination, there are no homogeneous quality standards followed throughout the country for it to be used as a screening method.
Is information about the importance of early detection of breast cancer readily available to women in Brazil?
Information concerning screening is widespread in the country, from
government, medical societies and NGOs. The disadvantages are not always discussed, either by the media or by the doctors who attend the women. There is also disagreement about the age of onset for mammographic screening between the government guidelines, which recommend mammography from 50 years of age, and medical societies that suggest beginning screening at age 40.
EUSOBI meets… Brazil
Published on : Mon, 21 Sep 2015
UltraDrape is an innovative dressing designed for use during Ultrasound-Guided Peripheral Intravenous (UGPIV) that provides dual-action barrier and securement in one.
A breakthrough in biopsy efficiency The Brevera system streamlines the entire breast biopsy process from start to finish – with real-time imaging for instant verification and automated post-biopsy specimen handling. This has the potential to...
Introducing a new chapter in ultrasound visualization technology. X-Porte was developed from the ground up to incorporate a breakthrough, proprietary beam-forming technology: XDI (Extreme Definition Imaging). This signal analysis algorithm shapes...
Transform the breast imaging patient experience The SmartCurve system provides a curved compression surface that offers a more comfortable patient experience without compromising image quality, exam time, dose or workflow.1 The SmartCurve system is...
Remarkable image quality, right at the point of care. The Trident system revolutionizes breast tissue imaging by incorporating a micro-focused tube, unique specimen image processing algorithms and amorphous selenium direct digital detector. The...